



#GP/1632
10-24-00
48
11-7-00
P12.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Kate Dora Games, Dale B. Schmidt, Lisa C. McConlogue, Peter A. Seubert and Russell E. Rydel

Serial No.: 09/149,718

Art Unit: 1632

Filed: September 8, 1998

Examiner: Crouch, D

For: *Method for Identifying Alzheimer's Disease Therapeutics Using Transgenic Animal Models*

RECEIVED

NOV 02 2000

TECH CENTER 1600/2800

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including sixteen (16) pages of Form PTO-1449 and copies of the documents cited therein.

Enclosed is a check for \$240.00 representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first office action on the merits under 37 C.F.R. §1.97(c). It is believed that no additional fees are required with this submission.

However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 01-2507.

10/30/2000 CCHAU1 00000025 09149718

01 FC:126

240.00 DP

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,666,829	05-19-1987	Glennner et al.	435/6
4,736,866	04-12-1998	Leder et al.	800/1
4,873,191	10-10-1989	Wagner et al.	435/172.3
5,134,062	07-28-1992	Blass	435/7.21
5,200,339	04-06-1993	Abraham	435/212

RECEIVED

NOV 02 2000

TECH CENTER 1600/2900

5,234,814	08-10-1993	Card et al.	435/7.21
5,441,870	08-15-1995	Seubert et al.	435/7.1
5,547,841	08-20-1996	Marotta et al.	435/6
5,877,399	03-02-1999	Hsiao et al.	800/2

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 123 527 B1	01-17-1990	The Wistar Institute	EP
0 171 496 B1	05-26-1993	Research Development Corporatoin of Japan	EP
0 173 494 A2	03-05-1986	The Board of Trustees of the Leland Stanford Junior University	EP
0 184 187 A2	06-11-1986	Teijin Limited	EP
0 653 154 A2	05-17-1995	Hoechst Japan Limited	EP
WO 86/01533	03-13-1986	Celltech Limited	PCT
WO87/02671	05-07-1987	International Genetic Engineering, Inc.	PCT
WO 91/16628	10-31-1991	The Regents of the University of California	PCT
WO 92/00521	01-09-1992	Case Western Reserve University	PCT
WO 92/09699	06-11-1992	L.F. Will & CIE S.A.	PCT
WO 94/00569	01-06-1994	Genpharm International	PCT
WO 96/18900	06-20-1996	Ramot-Univ. Authority for Applied Research and Industrial Development Ltd.	PCT

Publications

"Alzheimer's assault," *Science* 255(5048):1059 (1992).

ABRAHAM, et al., "A calcium-activated protease from Alzheimer's disease brain cleaves at the N-terminus of the amyloid β -protein," *Biochem. Biophys. Res. Comm.* 174:790-96 (1991).

ALI, et al., "More transgenic mouse studies of Alzheimer amyloid precursor (AAP) proteins and derivatives," *Society for Neuroscience Abstracts*, 18:1445 (presentation 616.9) (1992).

ALLISON, et al., "Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic B cells," *Nature* (333)6173:529-33 (1988).

ANTAL, et al., "Animal models of Alzheimer's, Parkinson's and Huntington's disease, A minireview," *Neurobiology (Bp)* 1(2):101-22 (1993).

BARTON, "Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease," *Neurodegeneration* 5:213-18 (1996).

BLASS, "Immunologic treatment of Alzheimer's disease," *The New England Journal of Medicine* 341(22):1694-95 (1999).

BREWER, "A G to C transversion in codon 258 of the α -subunit of β -hexosaminidase A in an infant Tay-Sachs disease patient," *Human Mutation* 2:496-97 (1993).

BRICE, et al., "Absence of the amyloid precursor protein gene mutation (APP717: Val->Ile) in 85 cases of early onset Alzheimer's disease," *J Neurol, Neurosurg, Psychiatry* 56(1):112-3 (1993).

CAIRNS, et al., " β A4 protein deposition in familial Alzheimer's disease with the mutation in codon 717 Of the beta A4 amyloid precursor protein gene and sporadic Alzheimer's disease," *Neurosci Lett.* 149(2):137-40 (1993).

CARLSON, et al., "Genetic modification of the phenotypes produced by amyloid precursor protein overexpression in transgenic mice," *Human Molecular Genetics* 6(11):1951-59 (1997).

CHAPMAN, et al., "Impaired synaptic plasticity and learning in aged amyloid precursor protein trasgenic mice," *Nature Neuroscience* 2(3):271-76 (1999).

CRAWFORD, et al., "Alzheimer's disease untangled," *BioEssays* (14)11:729 (1992).

DAVIS, et al., "An Alzheimer's disease-linked PS1 variant rescus the developmental abnormalities of PS1-deficient embryos," *Neuron* 20:603-09 (1998).

DE STROOPER, et al., "Study of the synthesis and secretion of normal and artificial mutants of murine amyloid precursor protein (APP): cleavage of APP occurs in a late compartment of the default secretion pathway," *J Cell Biol.* 121(2):295-304 (1993).

DOVEY, et al., "Cells with a familial Alzheimer's disease mutation produce authentic Beta-peptide," *Neuroreport.* Aug;4(8):1039-42 (1993).

DUFF, "Alzheimer transgenic mouse models come of age," *TINS* 20(7):279-80 (1997).

DUFF, "Modeling Alzheimer's disease in transgenic mice," *J Florida M.A.* 91(9):625-28 (1994).

DUFF, "Recent work on Alzheimer's disease transgenics," *Curr Opin Biotech* 9:561-64 (1998).

DUFF, "Transgenic models for Alzheimer's disease," *Neuropathology and Applied Neurobiology* 24:101-03 (1998).

DUFF, et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," *Nature* 383:710-13 (1996).

ERICKSON, "Model mice. Transgenic animals and Alzheimer's research," *Sci Am* 265(3):34 (1991).

FELSENSTEIN, et al, "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," *Neurosci Lett.* 152:185-89 (1993).

FIDANI, et al., "Screening for mutations in the open reading frame and promoter of the β -amyloid precursor protein gene in familial Alzheimer's disease: Identification of a further family with APP717 Val-->Ile," *Hum Mol Genet.* 1(3):165-68 (1992).

FISHER, et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," *Proc Natl Acad Sci USA* 88(5):1779-82 (1991).

FRANCIS, et al., "Animal and drug modelling for Alzheimer synaptic pathology," *Progress in Neurobiology* 39:517-45 (1992).

FRASER, et al., "Biochemistry and Alzheimer's disease amyloid plaques," *Clin Biochem* 46:339-49 (1993).

FRAUTSCHY, et al., "Microglial response to amyloid plaques in APPsw transgenic mice," *American Journal of Pathology* 152(1):307-17 (1998).

FUKUCHI, et al., "High levels of circulating β -amyloid peptide do not cause cerebral β -amyloidosis in transgenic mice," *American Journal of Pathology* 149(1):219-27 (1996).

FUKUCHI, et al., "Intestinal β -amyloidosis; transgenic mice," *Society for Neuroscience Abstracts* 19:1035 (1993).

FORSS-PETTER, et al., "Transgenic mice expressing β -galactosidase in mature neurons under neuron-specific enolase promoter control," *Neuron* 5(2):187-97 (1990).

GALLAGHER, et al., "Animal models of normal aging: Relationship between cognitive decline and markers in hippocampal circuitry," *Behav Brain Res.* 57(2):155-62 (1993).

GANDY, et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," *Trends Pharmacol Sci.* 13(3):108-13(1992).

GLENNER, et al., "Alzheimer's disease and Down's Syndrome: Sharing of unique cerebrovascular amyloid fibril protein," *Biochem. Biophys. Res. Commun.* 122:1131-35 (1984).

GODING, "Production and application of monoclonal antibodies in cell biology, biochemistry and immunology," in Monoclonal Antibodies: Principles and Practice, Ch. 3, pp. 56-74, (Academic Press, London 1984).

GOLDE, et al., "Production of amyloid β protein from normal amyloid β -protein precursor (β APP) and the mutated β APPS linked to familial Alzheimer's disease," *Ann. N Y Acad. Sci.*, 695:103-08 (1993).

GOVERMAN, et al., "Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity," *Cell* 72:551-560 (1993).

GREAVES, et al., "A transgenic mouse model of sickle cell disorder," *Nature* (343):183-85 (1990).

GREENBERG, "Yet more transgenic mouse studies of Alzheimer amyloid precursor (APP)," *Society for Neuroscience Abstracts* 19:1035 (1993).

GREENBERG, et al., "Transgenic mouse studies for Alzheimer amyloid precursor (AAP) proteins and derivatives," *Society for Neuroscience Abstracts*, Vol 18:1445 (presentation 616.7) (1992).

HAASS, et al., "The Swedish mutation causes early-onset Alzheimer's disease by β -secretase cleavage within the secretory pathway," *Nature Medicine* 1(12):1291-96 (1995).

HAASS, et al., "Amyloid β -peptide is produced by cultured cells during normal metabolism," *Nature* 359:322-325 (1992).

HAMMER, et al., "Partial correction of murine hereditary growth disorder by germ-line incorporation of a new gene," *Nature* 311:65-67 (1984).

HARDY, "New insights into the genetics of Alzheimer's disease," *Ann Med* 28(3):255-58 (1996).

HARDY, "The Alzheimer family of diseases: many etiologies, one pathogenesis?," *Proc Natl Acad Sci USA* 94(6):2095-97 (1997).

HOEWSCHKE, et al., "The 5'-flanking region of the rat synapsin I gene directs neuron-specific and developmentally regulated reporter gene expression in transgenic mice," *J Biol Chem.* 268(35):26494-02 (1993).

HOLCOMB, et al, "Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant *amyloid precursor protein* and *presenilin 1* transgenes," *Nature Medicine* 4(1):97-100 (1998).

HOLTZMAN, et al., "Molecular studies in Alzheimer's disease," *Trends Biochem. Sci.*, 16(4):140-4 (1991).

HOWLAND, et al., "Neuron-specific expression of human β -amyloid precursor protein (APP) in transgenic mice," *Society for Neuroscience Abstracts* 19:1035 (1993).

HOWLAND, et al., "Modulation of secreted β -amyloid precursor protein and amyloid β -peptide in brain cholesterol," *J Biol Chem.* 273(26):16576-82 (1998).

HSIAO, "A proposed strategic research program for Alzheimer's disease," *Neurobiology of Aging* 15(2):S112-S115 (1994).

HSIAO, "From prion diseases to Alzheimer's disease," *J. Transm Suppl* 49:135-44 (1997).

HSIAO, "Transgenic mice expressing Alzheimer amyloid precursor proteins," *Experimental Gerontology* 33(718):883-89 (1998).

HSIAO, "Understanding the biology of β -amyloid precursor proteins in transgenic mice," *Neurobiology of Aging* 16(4):705-06 (1995).

HSIAO, et al., "Molecular genetics and transgenic model of Gertsman-Straussler-Scheinker disease," *Alzheimer Dis Assoc Disord* 5(3):155-62 (1991).

HSIAO, et al., "Spontaneous neurodegeneration in transgenic mice with mutant prion protein," *Science* 250:1587-90 (1990).

HSIAO, "Strain dependent and invariant features of transgenic mice expressing Alzheimer amyloid precursor proteins," *Progress in Brain Research* 117:335-41 (1998).

HYMAN, et al., "Kunitz protease inhibitor-containing amyloid β protein precursor immunoreactivity in Alzheimer's disease," *J. Neuropath. Exp. Neurol.* 51:76-83 (1992).

IADECOLA, et al., "SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein," *Nature Neuroscience* 2(2):157-161 (1999).

IRIZARRY, et al., "APP_{sw} Transgenic mice develop age-related A β deposits and neuropil abnormalities, but no neuronal loss in CA1," *J Neuropathol Exp Neurol.* 56(9):965-73 (1997).

IWAMOTO, et al., "Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene," *Br J Cancer*. 67(3):504-47 (1993).

JAN & JAN, "Receptor-regulated ion channels," *Curr Opin Cell Biol* 9(2):155-60 (1997).

JOHNSTON-WOOD, et al., "Amyloid precursor protein processing and A β 42 deposition in a transgenic mouse model of Alzheimer disease," *Proc Natl Acad Sci USA* 94(4):1550-55 (1997).

JONES, et al., "Mutation in codon 713 of the β amyloid precursor protein gene presenting with Schizophrenia," *Genetics*, 1:306-309 (1992).

JOYNER, et al., "Gene targeting: A practical approach," Oxford Press (1993).

KEFFER, et al., "Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis," *EMBO* 10(3):4025-31 (1991).

KENNEDY, et al., "Familial Alzheimer's disease. A pedigree with a mis-sense mutation in the amyloid precursor protein gene (amyloid precursor protein 717 Valine-->Glycine)," *Brain* 116 (pt 2):309-24 (1993).

KENNEDY, et al., "Only kunitz-inhibitor-containing isoforms of secreted Alzheimer amyloid precursor protein show amyloid immunoreactivity in normal cerebrospinal fluid," *Neurodegeneration* 1:59-64 (1992).

KOLIATSOS, et al., "Neurotrophic strategies for treating Alzheimer's disease: Lessons from basic neurobiology and animal models," *Ann. N Y Acad. Sci.*, 695:292-99 (1993).

KONIG, et al., "Identification and differential expression of a novel alternative splice isoform of the BA4 amyloid precursor protein (App) mRNA in leukocytes and brain microglial cells," *JBC* 267:10804-09 (1992).

KORF, et al., "S-antigen and rodopsin immunoreactions in midline brain neoplasms of transgenic mice: Similarities to pineal cell tumors and certain medulloblastomas in man," *J Neuropathol Exp Neurol*. 49(4):424-37 (1990).

KOZAK, "The scanning model for translation: An update," *J. Cell Biology* 108:229-41 (1989).

KOZLOWSKI et al., "The neurotoxic carboxy-terminal fragment of the Alzheimer amyloid precursor binds specifically to a neuronal cell surface molecule: Ph dependence of the neurotoxicity and the binding," *J. Neurosci.*, 12(5):1679-87 (1992).

KULJIS, et al., "Alzheimer-like diffuse amyloid plaques can be induced in transgenic mice expressing human $\alpha 1$ -antichymotrypsin," *Soc. Neurosci. Abstr.* 9(2):1035 (1993).

KUMAR, "Mutations at codon 717 of the beta-amyloid precursor protein gene are a cause of Alzheimer's disease," *Indian J Exp Biol.* 30(2):156 (1992).

LAMB, et al., "Altered metabolism of familial Alzheimer's disease-linked amyloid precursor protein variants in yeast artificial chromosome transgenic mice," *Human Molecular Genetics* 6(9):1535-41 (1997).

LAMB, et al., "Amyloid production and deposition in mutant *amyloid precursor protein* and *presenilin-1* yeast artificial chromosome transgenic mice," *Nature Neuroscience* 2(8):695-97 (1999).

LANNFELT, et al., "Low frequency of the APP 670/671 mutation in familial Alzheimer's disease in Sweden," *Neurosci Lett.* 153(1):85-7 (1993).

LAVIGUEUR, et al., "High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the P53 oncogene," *Molecular and Cellular Biology* (9)9:3982-91 (1989).

LENDON, et al., "Exploring the etiology of Alzheimer disease using molecular genetics," *Jama* 277(10):825-31 (1997).

LIEBERBURG, Abstract 421.15, "Expression of human Alzheimer's amyloid precursor protein in transgenic mice," *Society for Neuroscience Abstracts* 19:1035 (1993).

LUO, et al., "Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for *App1* Gene," *Neuron* 9(4):595-605 (1992).

MARX, "New lead to an Alzheimer's mouse?," *Science* 261(5128):1520 (1993).

MCPHEI, et al., "Neuronal expression of β -amyloid precursor protein Alzheimer mutations causes intracellular accumulation of a C-terminal fragment containing both the amyloid β and cytoplasmic domains," *J. Biol. Chem.* 272:24743-46 (1997).

MILLER, et al., "Alzheimer's disease: Transgenic models to test new chemicals and pharmaceuticals," *Carr Opin Biotechnol* 6:683-686 (1992).

MUCKE, et al., "High-level neuronal expression of $A\beta_{1-42}$ in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation," *J. Neuroscience* 20(11):4050-58 (2000).

MULLAN, "Familial Alzheimer's disease: Second gene locus located," *BMJ* 305(6862):1108-9 (1992).

MULLAN, et al., "Genetic and molecular advances in Alzheimer's disease," *Trends Neurosci.* 16(10):398-403 (1993).

MULLINS, et al., "Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene," *Nature* 344:541-44 (1990).

MURAI, et al., "Twofold overexpression of human β -amyloid precursor proteins in transgenic mice does not affect the neuromotor, cognitive, or neurodegenerative sequelae following experimental brain surgery," *The Journal of Comparative Neurology* 392:428-38 (1998).

NEVE, et al., "Brain transplants of cells expressing the carboxyl-terminal fragment of the Alzheimer amyloid protein precursor cause specific neuropathology *in vivo*," *Proc. Natl. Acad. Sci. USA* 89(8):3448-52 (1992).

NGUYEN, et al., "The pathophysiological significance of nondesmoglein targets of pemphigus autoimmunity," *Arch Dermatol.* 134:971-80 (1998).

NUSSBAUM, et al., "Alzheimer's disease and amyloid protein--In (transgenic) mice and man," *Harefuah* (Hebrew) 123(9):362-64 (1992).

OLTERSDORF, et al., "The secreted form of the Alzheimer's amyloid precursor protein with the kunitz domain is protease nexin-II," *Nature* 341:144-47 (1989).

PALMERT, et al., "Soluble derivatives of the B amyloid protein precursor of Alzheimer's disease are labeled by antisera to the B amyloid protein," *Biochem. Biophys. Res. Comm.* 165:182-88 (1989).

PALMERT, et al., "The β -amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid," *Proc. Natl. Acad. Sci USA* 86:6338-42 (1989).

PAPPOLLA, et al., "Evidence of oxidative stress and *in vivo* neurotoxicity of β -amyloid in transgenic mouse model of Alzheimer's disease," *Amer. J. Path.* 152(4):871-77 (1998).

PAVLIN, "Brain amyloid in Alzheimer's disease--A new experimental model," *Neurol Croat* 41(4):227-34 (1992).

PEARSON, et al., "Nicotine intake and Alzheimer's disease," *BMJ* 303:361 (1991).

PERRAUD, et al., "The promotor of the human Cystic Fibrosis transmembrane conductance regulator gene directing SV40 T antigen expression induces malignant proliferation of ependymal cells in transgenic mice," *Oncogene* 5:993-97 (1992).

PRICE, et al., "Alzheimer's disease-type brain abnormalities in animal models," *Prog Clin Biol Res.* 379:271-87 (1992).

PULLIAM, et al., "Use of aggregating brain cultures to study the replication of herpes simplex virus types 1 and 2 in central nervous system tissue," *J. Virol. Met.* 9:301-16 (1984).

REAUME, "Enhanced amyloidogenic processing of the β -amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and 'humanized' A β sequence," *J. Biol. Chem.* 271(38):23380-88 (1996).

ROBAKIS, et al., "An alternative secretase cleavage produces soluble Alzheimer amyloid precursor protein containing a potentially amyloidogenic sequence," *Soc. Neurosci.*, Abstract No. 15.5, (1993).

ROCH, et al., "Biologically active domain of the secreted form of the amyloid beta/A4 protein precursor," *Ann N Y Acad. Sci.* 695:149-57 (1993).

ROSSOR, et al., "Alzheimer's Disease families with amyloid precursor protein mutations," *Ann N Y Acad Sci.* 695:198-202 (1993).

RYAN, et al., "Human sickle hemoglobin in transgenic mice," *Science* 247:566-68 (1990).

SAHASRABUDHE, et al., "Release of amino-terminal fragments from amyloid precursor protein reporter and mutated derivatives in cultured cells," *J. Biol. Chem.*, 267(35):25602-8 (1992).

SARVETNICK, et al., "Insulin-dependent diabetes mellitus induced in transgenic mice by ectopic expression of class II MHC and interferon-gamma," *Cell* (52):773-82 (1988).

SAVAGE, et al., "Human amyloid precursor protein expression in transgenic mice as a model of Alzheimer's disease: A search for pathology," *Society for Neuroscience Abstracts* 19:1035 (1993).

SAVAGE, et al., "Turnover of amyloid β -protein in mouse brain and acute reduction of its by phorbol ester," *Journal of Neuroscience* 18(5):1743-52 (1998).

SCHENK, et al., "The potential utility of transgenic mice harboring β -amyloid precursor protein," *Neurobiology of Aging* 16(4):711-13 (1995).

SCHEUNER, et al., "Secreted amyloid β -protein similar to that in the senile plaques of Alzheimer's disease is increased *in vivo* by the presenilin 1 and 2 and *APP* mutations linked to familial Alzheimer's disease," *Nature Medicine* 2(8):864-90 (1996).

SCOTT, et al., "Chimeric prion protein expression in cultured cells and transgenic mice," *Protein Science* 1:986-97 (1992).

SCOTT, et al., "Inability to detect beta-amyloid protein precursor mRNA in Alzheimer plaque-associated Microglia," *Exp. Neurol.*, 121(1):113-8 (1993).

SCOTT, et al., "The processing of native and mutant APP751 in human 293 cells," *Neurobiology of Aging Third International Conference on Alzheimer's Disease and Related Disorders* 13 (Suppl. 1):310 (1992).

SCOTT, et al., "Transgenic mice expressing hamster prion protein produce species-specific scrapie infectivity and amyloid plaques," *Cell* 59:847-857 (1989).

SELKOE, et al., " β -Amyloid precursor protein of Alzheimer disease occurs as 110-to 135-kilodalton membrane-associated proteins in neural and nonneural tissues," *Proc. Nat. Acad. Sci. USA* 85:7341-45 (1988).

SELKOE, "Alzheimer's disease: Genotypes, phenotype, and treatments," *Science* 275(5300):630-31 (1997).

SELKOE, "The molecule pathology of Alzheimer's disease," *Neurom.* 6(4):487-98 (1991).

SHIOSAKA, "Attempts to make models for Alzheimer's disease," *Neurosci Res* 13(4):237-55 (1992).

SIMAN, et al., "Processing of the beta-amyloid precursor. Multiple proteases generate and degrade potentially amyloidogenic fragments," *J. Biol. Chem.*, 268(22):16602-9 (1993).

SISODIA, et al., "Amyloidogenesis in Alzheimer's disease: Basic biology and animal models," *Curr Opin Neurobiol* 2(5):648-52 (1992).

SISODIA, " β -amyloid precursor protein cleavage by a membrane-bound protease," *Proc Natl Acad Sci USA* 89(13):6075-79 (1992).

SMITH, et al., "Amyloid- β deposition in Alzheimer transgenic mice is associated with oxidative stress," *Journal of Neurochemistry* 70(5):2212-15 (1998).

SOFRONIEW, et al., "Transgenic modeling of neurodegenerative events gathers momentum," *Trends Neurosci.* 14(12):513-14 (1991).

STACEY, et al., "Perinatal lethal osteogenesis imperfecta in transgenic mice bearing an engineered mutant Pro-X1(I) collagen gene," *Nature* 332:131-36 (1988).

STOUT, et al., "Expression of human HPRT in the central nervous system of transgenic mice," *Nature* 317:250-52 (1985).

STURCHLER-PIERRAT, et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," *Proc. Natl. Acad. Sci.* 94:13287-92 (1997).

TOMITA, et al., "The presenilin 1 mutation (N141I) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid beta protein ending at the 42nd (or 43rd) residue," *Proc Natl Acad Sci USA* 94(5):2025-30 (1997).

THINAKARAN, et al., "Endoproteolysis of presenilin 1 and accumulation of processed derivatives *in vivo*," *Neuron* 17:181-90 (1996).

TRAVIS, "New piece in Alzheimer's puzzle," *Science* 261(5123):828-9 (1993).

TRUDEL, et al., "c-myc as an inducer of polycystic kidney disease in transgenic mice," *Kidney International* 39:665-71 (1991).

USAMI, et al., "The triplet of lysine residues (Lys724-Lys725-Lys726) of Alzheimer's amyloid precursor protein plays an important role in membrane anchorage and processing," *J Neurochem.* 61(1):239-46 (1993).

VAN DUIJN, et al., "Genetic transmission of Alzheimer's disease among families in a dutch population based study," *J Med Genet.* 30(8):640-46 (1993).

VIDAL, et al., "Sequencing of the Alzheimer's APP gene dutch variant (APP-D)," *Hum Mutat.* 2(6):496-67 (1993).

WANG, et al., "Tissue and development-specific expression of the human phenylalanine hydroxylase/chloramphenicol acetyltransferase fusion gene in transgenic mice," *The Journal of Biological Chemistry* 267:15105-10 (1992).

WELLS, et al., "Human dystrophin expression corrects the myopathic phenotype in transgenic Mdx mice," *Human Molecular Genetics* 1(1):35-40 (1992).

WESTPHAL, "Mouse models of human diseases," *Curr Opin Biotechnol.* 2(6):830-3 (1991).


ZHANG, et al., "Increased susceptibility to ischemic brain damage in transgenic mice overexpressing the amyloid precursor protein," *Journal of Neuroscience* 17(20):7655-61 (1997).

U.S.S.N.: 09/149,718
Filed: September 9, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Robert A. Hodges
Reg. No. 41,074

Dated: October 20, 2000


ARNALL GOLDEN & GREGORY, LLP
2800 One Atlantic Center
1201 West Peachtree Street
Atlanta, Georgia 30309-3450
(404) 873-8796
(404) 873-8797 (fax)

U.S.S.N.: 09/149,718
Filed: September 9, 1998
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: October 20, 2000


Kimberly L. Adams